Curis Overview

  • Status
  • Public

  • Employees
  • 24

Employees

  • Stock Symbol
  • CRIS

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.43
  • (As of Friday Closing)

Curis General Information

Description

Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Contact Information

Website
www.curis.com
Formerly Known As
Ontogeny
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 128 Spring Street
  • Building C - Suite 500
  • Lexington, MA 02421
  • United States
+1 (617)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 128 Spring Street
  • Building C - Suite 500
  • Lexington, MA 02421
  • United States
+1 (617)

Curis Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Curis Stock Performance

As of 20-Nov-2026, Curis’s stock price is $0.43. Its current market cap is $4.06M with 9.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.43 $0.47 $0.33 - $28.40 $4.06M 9.5M 4.27M $7.83

Curis Financials Summary

As of 30-Sep-2026, Curis has a trailing 12-month revenue of $1.14M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (1,994) 5,679 8,315 9,745
Revenue 1,138 9,443 10,908 10,023
EBITDA (19,515) (5,544) (44,339) (48,077)
Net Income (21,544) (7,582) (43,389) (47,413)
Total Assets 18,799 19,966 41,265 77,282
Total Debt 740 1,618 2,954 2,794
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Curis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Curis‘s full profile, request access.

Request a free trial

Curis Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Curis‘s full profile, request access.

Request a free trial

Curis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and pre
Biotechnology
Lexington, MA
24 As of 2026

San Diego, CA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Curis Competitors (101)

One of Curis’s 101 competitors is ImmunityBio, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ImmunityBio Formerly VC-backed San Diego, CA
Aura Biosciences Formerly VC-backed Boston, MA
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Sorrento Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 101 competitors. Get the full list »

Curis Patents

Curis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025208000-A1 Methods of treating cancer in patients with altered protein expression Pending 29-Mar-2024
WO-2025174879-A1 Methods of reducing or eliminating measurable residual disease Pending 12-Feb-2024
AU-2024368208-A1 Methods of treating cancer associated with reduced interleukin 1 beta expression Pending 27-Oct-2023
EP-4798194-A1 Methods of treating cancer associated with reduced interleukin 1 beta expression Pending 27-Oct-2023
WO-2025090844-A1 Methods of treating cancer associated with reduced interleukin 1 beta expression Inactive 27-Oct-2023 A61P35/00
To view Curis’s complete patent history, request access »

Curis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Curis Acquisitions (2)

Curis’s most recent deal was a Merger/Acquisition with Creative Biomolecules. The deal was made on 31-Jul-2000.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Creative Biomolecules 31-Jul-2000 Merger/Acquisition Drug Discovery
Reprogenesis 31-Jul-2000 Merger/Acquisition Other Pharmaceuticals and Biotechnology
To view Curis’s complete acquisitions history, request access »

Curis ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

38.14 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Curis’s complete esg history, request access »

Curis FAQs

  • Where is Curis headquartered?

    Curis is headquartered in Lexington, MA.

  • What is the size of Curis?

    Curis has 24 total employees.

  • What industry is Curis in?

    Curis’s primary industry is Biotechnology.

  • Is Curis a private or public company?

    Curis is a Public company.

  • What is Curis’s stock symbol?

    The ticker symbol for Curis is CRIS.

  • What is the current stock price of Curis?

    As of 20-Nov-2026 the stock price of Curis is $0.43.

  • What is the current market cap of Curis?

    The current market capitalization of Curis is $4.06M.

  • What is Curis’s current revenue?

    The trailing twelve month revenue for Curis is $1.14M.

  • Who are Curis’s competitors?

    ImmunityBio, Aura Biosciences, Immunocore Holdings, Adaptimmune Therapeutics, and Sorrento Therapeutics are some of the 101 competitors of Curis.

  • What is Curis’s annual earnings per share (EPS)?

    Curis’s EPS for 12 months was $7.83.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process